These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 25378905)

  • 1. Preclinical profile of cabazitaxel.
    Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
    Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
    Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
    Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
    Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
    Ecstein-Fraisse E; Su Z
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabazitaxel, a new taxane with favorable properties.
    Bouchet BP; Galmarini CM
    Drugs Today (Barc); 2010 Oct; 46(10):735-42. PubMed ID: 21076710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
    de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
    Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
    Paller CJ; Antonarakis ES
    Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
    Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
    de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
    Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
    PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
    Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Chao OS; Goodman OB
    Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies.
    Xie B; Wan J; Chen X; Han W; Wang H
    Mol Cancer Ther; 2020 Mar; 19(3):822-834. PubMed ID: 31848296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
    Reynolds CP; Kang MH; Maris JM; Kolb EA; Gorlick R; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2015 Nov; 62(11):1897-905. PubMed ID: 26154614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
    Pal SK; Twardowski P; Sartor O
    Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.